The interleukin-17 (IL-17) family is involved in innate immunity regulation and plays a crucial role in inflammatory and autoimmune disorders by sustaining inflammation during the onset and progression of diseases such as rheumatoid arthritis (RA), psoriasis or inflammatory bowel disease (IBD). Researchers from the University of Naples have reported on a new biological entity, Ab-IPL-IL-17, that displays potent anti-inflammatory activity in preclinical testing.